Voyager Therapeutics Past Earnings Performance
Past criteria checks 0/6
Voyager Therapeutics has been growing earnings at an average annual rate of 40.4%, while the Biotechs industry saw earnings growing at 15% annually. Revenues have been growing at an average rate of 14.5% per year.
Key information
40.4%
Earnings growth rate
40.8%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 14.5% |
Return on equity | -0.9% |
Net Margin | -2.6% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise
Mar 15Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier
Mar 08What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates
Mar 04Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement
Jan 04Voyager stock rises as Pfizer opts to use AAV capsid for neurologic disease target
Oct 04Voyager Therapeutics hires new finance chief
Sep 07Voyager Therapeutics GAAP EPS of -$0.50 misses by $0.02
Aug 04Looking Back In On Voyager Therapeutics
Jun 08Need To Know: Analysts Just Made A Substantial Cut To Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Estimates
May 12Voyager Does A Reboot After First Generation Failures
Mar 25Companies Like Voyager Therapeutics (NASDAQ:VYGR) Could Be Quite Risky
Feb 07Voyager Therapeutics: Another Year, Another Deal
Nov 21Some Analysts Just Cut Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Estimates
Aug 11Newsflash: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Analysts Have Been Trimming Their Revenue Forecasts
Jul 18Revenue & Expenses BreakdownBeta
How Voyager Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 119 | -3 | 35 | 0 |
31 Dec 23 | 250 | 132 | 36 | 0 |
30 Sep 23 | 158 | 52 | 34 | 0 |
30 Jun 23 | 195 | 96 | 33 | 0 |
31 Mar 23 | 191 | 99 | 32 | 0 |
31 Dec 22 | 41 | -46 | 31 | 0 |
30 Sep 22 | 71 | -17 | 31 | 0 |
30 Jun 22 | 31 | -60 | 32 | 0 |
31 Mar 22 | 32 | -71 | 35 | 0 |
31 Dec 21 | 37 | -71 | 37 | 0 |
30 Sep 21 | 16 | -93 | 37 | 0 |
30 Jun 21 | 132 | 18 | 37 | 0 |
31 Mar 21 | 160 | 39 | 35 | 0 |
31 Dec 20 | 171 | 37 | 35 | 0 |
30 Sep 20 | 197 | 40 | 37 | 0 |
30 Jun 20 | 100 | -61 | 37 | -5 |
31 Mar 20 | 117 | -41 | 37 | 0 |
31 Dec 19 | 104 | -44 | 36 | 0 |
30 Sep 19 | 74 | -54 | 40 | 0 |
30 Jun 19 | 55 | -59 | 38 | 5 |
31 Mar 19 | 12 | -96 | 36 | 0 |
31 Dec 18 | 8 | -88 | 34 | 0 |
30 Sep 18 | 12 | -78 | 26 | 0 |
30 Jun 18 | 11 | -81 | 24 | 0 |
31 Mar 18 | 10 | -74 | 22 | 0 |
31 Dec 17 | 10 | -71 | 20 | 0 |
30 Sep 17 | 6 | -74 | 18 | 0 |
30 Jun 17 | 8 | -59 | 16 | 0 |
31 Mar 17 | 11 | -50 | 15 | 0 |
31 Dec 16 | 14 | -40 | 13 | 0 |
30 Sep 16 | 17 | -34 | 13 | 0 |
30 Jun 16 | 18 | -32 | 12 | 0 |
31 Mar 16 | 20 | -30 | 12 | 0 |
31 Dec 15 | 17 | -38 | 10 | 0 |
30 Sep 15 | 12 | -35 | 8 | 0 |
30 Jun 15 | 7 | -32 | 7 | 0 |
31 Mar 15 | 3 | -30 | 6 | 0 |
31 Dec 14 | 0 | -18 | 5 | 0 |
Quality Earnings: VYGR is currently unprofitable.
Growing Profit Margin: VYGR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VYGR is unprofitable, but has reduced losses over the past 5 years at a rate of 40.4% per year.
Accelerating Growth: Unable to compare VYGR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VYGR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: VYGR has a negative Return on Equity (-0.89%), as it is currently unprofitable.